Immunotherapy for Post-Transplant Lymphoproliferative Disorders

Post-transplant lymphoproliferative disorder (PTLD) encompasses a range of lymphoid proliferations triggered by immunosuppression in organ and stem cell transplant recipients, from benign hyperplasia to aggressive lymphoma. Traditional management—reduction of immunosuppression, antiviral agents and anti-CD20 monoclonal antibodies—often fails to achieve sustained remission in refractory cases. Advances in immunotherapy have ushered in personalised cellular approaches that harness T-cell immunity against Epstein-Barr virus (EBV), the principal driver of most PTLD. Adoptive transfer of EBV-specific T lymphocytes restores pathogen-targeted surveillance and directly eradicates malignant clones while preserving graft integrity. Innovations include rapid generation of partially HLA-matched T-cell products, multi-antigen platforms and third-party cell banks, each demonstrating enhanced safety, feasibility and response rates. Together with emerging bispecific antibodies and checkpoint modulators, these strategies herald a new era of tailored treatments for PTLD, balancing efficacy with minimised toxicity.

Research from Nature Portfolio

Recent clinical studies have demonstrated the feasibility and efficacy of virus-specific T-cell therapy to prevent and treat EBV-driven lymphoproliferation following transplantation. A phase II trial in paediatric stem cell transplant recipients evaluated partially HLA-matched T-cell infusions targeting CMV, EBV and adenovirus. Over 60% of patients experienced significant reductions in viral load, with sustained T-cell engraftment and minimal toxicity. Clinical responses correlated with lymphocyte recovery metrics, highlighting both the importance of early immune reconstitution and the role of co-morbid factors such as corticosteroid use. This work underlines the potential of off-the-shelf cellular products to bridge critical periods of vulnerability in immunocompromised hosts.

Immunotherapy for Post-Transplant Lymphoproliferative Disorders publication trend

The graph below shows the total number of articles in immunotherapy for post-transplant lymphoproliferative disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Post-Transplant Lymphoproliferative Disorder (PTLD): Lymphoid proliferations ranging from benign hyperplasia to malignant lymphoma, arising in immunosuppressed transplant recipients.

Epstein-Barr Virus (EBV): A ubiquitous herpesvirus that drives B-cell transformation and is implicated in most PTLD cases.

Virus-Specific T Cells (VSTs): T lymphocytes selected or engineered to recognise viral antigens, used in adoptive immunotherapy.

Cytotoxic T Lymphocyte (CTL): A T-cell subtype capable of directly killing infected or malignant cells through antigen-specific mechanisms.

Human Leucocyte Antigen (HLA): Cell-surface proteins critical for antigen presentation and matching between donors and recipients in cellular therapies.

References

1. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nature Communications (2024).
2. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. Journal of Clinical Investigation (2023).
3. Establishment and operation of a Good Manufacturing Practice‐compliant allogeneic Epstein‐Barr virus (EBV)‐specific cytotoxic cell bank for the treatment of EBV‐associated lymphoproliferative disease. British Journal of Haematology (2014).
4. Virus-Specific T Cells for the Immunocompromised Patient. Frontiers in Immunology (2017).